Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
New Delhi, Oct 19 Drug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to advertise Tofacitinib extended-release pills, used to treat ulcerative colitis, in the American market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for the item which is the generic version of Pfizer”s Xeljanz XR tablets, Zydus Cadila said in a statement.
The medication is suggested for the once-daily treatment of adult patients with moderate to severe active ulcerative colitis (UC).
The drug will be manufactured at the group”s formulation manufacturing facility at the SEZ, Ahmedabad, the drug firm said.
The team currently has 308 approvals and has up to now filed over 390 abbreviated new drug applications (ANDAs) since the initiation of the filing procedure in 2003-04, it added. PTI MSS DRR DRR
